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INTRODUCTION
Burkitt lymphoma (BL) accounts for up to 50% of recorded
childhood cancers in countries in tropical Africa [1]. The annual
incidence in the Northwest Province of Cameroon is 4.54/100,000
children aged <15 years [2]. It mainly occurs in children aged
3–15 years, has a peak incidence between 6 and 8 years and is
more common in boys.
Common sites of disease in descending order are the abdomen
(lymphoid system, spleen, kidneys, liver, ovaries), face (orbit, man-
dible, maxilla), paraspinal (presenting as paraplegia), bone marrow,
and central nervous system. Lymph nodes, bone, the breast, and
testes may be involved. The tumor may double in size within
48 hours, and therefore requires urgent treatment. Historically, the
recorded long-term cure rate in Africa using single chemotherapy or
low dose combination chemotherapy agents has been <35% com-
pared to >90% cure rate achieved with intensive high dose chemo-
therapy and optimal supportive care in well resourced centers [3–5].
Recent studies have demonstrated that a >60% cure rate in BL is
possible with simple, inexpensive chemotherapy schedules and ap-
propriate matching supportive care [6].
This guideline provides diagnostic and therapeutic recommen-
dations that are affordable and effective, and can be applied safely
in a hospital with basic diagnostic and treatment facilities by
trained, dedicated nurses, and doctors.
The Pediatric Oncology in Developing Countries group (PODC)
has defined settings for the management of BL. In setting 0 the
minimal requirements for curative treatment are not met. Palliative
care should be provided. In setting 1 the minimal requirements for
diagnosis and treatment with curative intent are met. In setting 2 the
treatment facilities range between that of settings 1 and 3. In setting
3 all diagnostic and treatment facilities are available. This guideline
provides recommendations for setting 1.
MINIMAL REQUIREMENTS FOR SETTING 1
Investigations: The ability to obtain these investigations should
be available; fine needle aspirate (FNA), bone marrow aspirate,
cerebrospinal fluid cytology, ultrasound scans (USS), full blood
count, plain radiography, thick blood films for malaria staining or
RDTs (rapid diagnostic tests), stool and urine microscopy, HIV
serology, and sickling test.
Chemotherapy agents: These drugs are necessary: cyclophos-
phamide, methotrexate, vincristine, and hydrocortisone.
For supportive care: IV fluids, antibiotics, anti-fungals, acy-
clovir, analgesics, anti-vomiting drugs, and nutritional supplemen-
tation must be available. Palliative care is essential and financial
support to families is required.
DIAGNOSIS
The clinical presentation of BL is usually typical. Other lym-
phomas, leukemias, Wilms tumor, retinoblastoma, neuroblastoma,
and rhabdomyosarcoma, primary bone tumors, and dental pathol-
ogy need to be considered depending on the site of disease and
the age of the patient. BL usually grows faster than the other
tumors mentioned in the differential diagnosis. Abdominal masses
on USS are hypoechoic in appearance, and the scan may reveal
clinically unsuspected tumor [7]. A FNA of the tumor is the
standard diagnostic procedure in this setting [8]. Diagnostic pro-
cedures can be safely performed with ketamine anesthesia but
resuscitation equipment should be available. Examination of ce-
rebrospinal fluid, bone marrow, ascites, or pleural fluid may con-
firm the diagnosis. In some treatment centers cytology or
histopathology is not readily available, or the waiting time for
the report is too long to help in the acute management. Treatment
should then be started based on the clinical diagnosis.
STAGING OF THE TUMOR
The St Jude (Murphy) staging system for NHL in children is
recommended [9]. (Table I). About 15–20% of patients present
with stage I or II disease, 65–70% with stage III disease, and 15%
with stage IV disease [6]. Staging requires an abdominal
Treatment recommendations for endemic Burkitt lymphoma (BL)
in settings with only minimum requirements for curative treatment
(PODC setting 1) are described. The reported cure rate for endemic
BL is usually <50%. Facilities within setting 1 differ. Three treat-
ment schedules are proposed based on: (1) when accurate staging is
not possible, (2) when staging is possible and for (3) relapses and
poor responders to primary therapy. A literature review and person-
al experience were used to formulate the recommendations.
Recorded 1-year event free survival was 48% for treatment 1,
61% for treatment 2, and 35% for the rescue treatment. Pediatr
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ultrasound and cytological examination of the CSF and bone
marrow. The intensity of treatment and outcome is related to
the stage of disease. If staging is not possible, the same treatment
schedule should be considered for all patients [10]. If surgery has
been undertaken (though this is not recommended) the tumor is
rarely able to be completely resected. All abdominal disease is
classified as St Jude stage III. Paraspinal disease presents as
paraplegia with or without incontinence. If other CNS signs
such as cranial nerve palsies and papiloedema are absent, and
the CSF sample does not contain BL cells, this is classified as
stage III disease.
TREATMENT
The guardian should be fully informed about the disease and
proposed management, including the cost (if any) of treatment.
Full contact details and a photograph of the patient and guardian
facilitate follow-up. Informed consent must be obtained. Only
treatment options with a relative low drug cost, and requiring
basic supportive care, are included in this guideline. The potential
gain in cure rate with high dose more intensive (and expensive)
chemotherapy, was lost from a higher morbidity and mortality
rate of treatment complications in a mainly malnourished cohort
of patients with BL [11]. Generic medicines are less expensive,
and can be procured from many reliable sources. Various low
dose combination chemotherapy treatment options containing
different combinations of cyclophosphamide (CPM), vincristine,
oral and intrathecal methotrexate, prednisone, and arabinoside C
were used in East and West Africa. A 25% long-term (>10
years) survival rate was recorded in Uganda. The best survival
rate (of 41%) with these combinations was in Ghana. These
protocols will not be discussed, because better treatment options
are now available [4,12]. Single drug treatment with CPM
40 mg/kg at 2- to 3-week intervals for four to six doses, can
result in long-term cures [3,13,14]. Intravenous and oral CPM
have comparable pharmacokinetics and can be interchanged at
the same dose per kilogram body weight [15]. Tablets are easier
to administer and cost less. The routine administration of IT
MTX together with CPM induction chemotherapy markedly
reduces the risk for a CNS relapse [12]. We recommend a
dose of 12.5 mg intrathecal methotrexate and 12.5 mg hydro-
cortisone. This provides good CNS protection and allows for
two doses from one 25 mg vial of methotrexate. High frequency
(7 day intervals) CPM at 40 mg/kg þ IT MTX 12.5 mg and IT
HC 12.5 mg as induction in all patients, followed on Day 28 by
three additional pulses of CPM 40 mg/kg at 14-day intervals for
patients with stages III and IV disease, resulted in an overall
52% projected 12-month event free survival (EFS) [15].
A 50% EFS rate at 24 months was reported by the French
African Pediatric Oncology Group. Patients who had an incom-
plete response on Day 21 had a further two courses of COPM and
two courses of CYM. The cost of investigations, drugs and the
need for a higher level of supportive care, are however limiting
factors [16].
The response to treatment and the time to assess must be
defined. Patients without clinical detectable tumor may still
have disease detectable by abdominal USS, bone marrow, and/
or CSF examination. We define a complete clinical response as
disappearance of all clinical visible or palpable tumor and in
patients with abdominal disease, a residual tumor of 30 ml in
volume on abdominal ultrasound, 4 weeks after starting
chemotherapy.
Staging classifications have changed with time and must be
taken into account when interpreting the outcome of treatment in
older publications. The routine use of abdominal USS has made it
simpler to identify, monitor, and quantify abdominal disease.
Diagnostic and staging investigations should be performed on
admission. The response to treatment is judged on clinical exami-
nation and a repeat abdominal USS following three cycles of
treatment or after completing induction therapy and before start-
ing consolidation chemotherapy. We accept 12 months disease
free survival as a cure, as the risk for a relapse is <5% after
1 year. Therefore a 12-month follow-up period is required to
identify relapses, and to confirm the outcome. We recommend
the following three treatment schedules:
Higher Dose CPM With IT MTX and IT HC (When
Pathology Results Are Not Available and
Accurate Staging Is Impossible)
This treatment schedule was designed for use in patients with
presumed BL where delay in obtaining pathology results makes
diagnosis, and staging, impossible. A similar cumulative total
amount of CPM/kg was given as in the Malawi 2002 BL treat-
ment schedule, over a total period of 28 days. The projected 1-
year EFS rate 48%, and the toxicity were manageable [10,11].
Figure 1 illustrates the treatment flow sheet.
Risk-Adapted Treatment With CPM, IT MTX, IT
HC W Vincristine, and Methotrexate
Induction treatment with CPM þ IT MTX and IT HC was
followed by consolidation treatment with CPM, or CPM þ vin-
vincristine þ intravenous MTX. All patients received the same
TABLE I. The St Jude Staging System for NHL in Children
Stage I A single tumor (extranodal) or anatomic area (nodal)
excluding the mediastinum or abdomen
Stage II A single tumor (extranodal) with regional node
involvement
Two or more nodal areas on the same side of the
diaphragm
Two single (extranodal) tumors  regional node
involvement on the same side of the diaphragm
A primary gastrointestinal tract tumor  mesenteric
lymph node involvement that is grossly completely
resected
Stage IIIa Two single extranodal tumors on both sides of the
diaphragm
Two or more nodal areas on both sides of the
diaphragm
All primary intrathoracic tumors
All extensive primary unresectable intra-abdominal
disease
All primary paraspinal or epidural tumors (CNS and
CSF not involved)
Stage IV Any of the above with initial CNS or bone marrow
involvement
aElective surgery for presumed abdominal BL is not recommended
and abdominal tumors are classified as stage III disease.
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induction treatment. On Day 28 patients were allocated to main-
tenance chemotherapy in Risk Group 1, 2, or 3 according to the
initial stage, the clinical response, and the abdominal USS find-
ings (Table II). The overall projected 12-month EFS rate was
61%; 100% for stage I, 85% for stage II, 60% for stage III, and
27% for stage IV. The predictive value of the size of residual
abdominal lesions on Day 28 following induction with CPM
40 mg/kg on Days 1, 8, and 15 was confirmed in a separate
prospective study [17]. Figure 2 illustrates the treatment flow
charts (Table III).
MTX administration and leucovorin rescue (for patients in
Risk Group 3): an infusion is started with 5% dextrose water or
half strength dextrose/Darrows with 30 ml of 4% NaHCO3 added
per liter at a rate of 3 L/m2/24 hours, 4 hours before starting the
MTX infusion, and continue this for another 48 hours. The MTX
is reconstituted, added to 200 ml dextrose/water or 0.9% saline,
and infused over 3 hours. Leucovorin 15 mg tablets every
6 hours  7 doses needs to be started strictly 24 hours after
the start of the MTX infusion. A urine output of 3 ml/kg/hours
must be achieved. Methotrexate at this dose can be safely admin-
istered in the absence of third space fluid collections, and by
adhering to the recommended fluid regime and leucovorin
rescue [18].
Second Line Chemotherapy for Recurrent
and/or Refractory Disease
This treatment is recommended for patients with refractory or
recurrent disease. Patients who relapse following treatment with
only CPM and IT MTX, and patients who are not in clinical
remission on Day 28 following three courses of CPM and IT
MTX þ IT HC are offered rescue therapy which includes a
higher dose of CPM and vincristine sulfate. Thirty five percent
of patients in Malawi and in Cameroon achieved an overall 12-
month—EFS [19]. The median time to relapse with the CPM
containing protocols is <6 months. Relapses after 1 year (termed
late) from end of therapy and very late relapses (up to 4 years) do
occur rarely. It is not known (without molecular studies) if late
relapses are really a recurrence, or constitute a second, new BL
tumor. Our recommendation is to offer this treatment to patients
who relapse within 1 year. Patients who have failed Risk Group 3
treatment of the Cameroon 2008 BL protocol, and patients who
relapse after presenting with St Jude stage IV disease, are unlikely
to benefit from further chemotherapy (available in this setting).
Patients with confirmed BL that recurs after 1 year, are treated as
patients who present with BL for the first time. The indications for
palliative care should be clearly defined. Figure 3 illustrates the
treatment schedule.
The different treatment schedules listed above are from non-
randomized clinical studies, and provide a base for future ran-
domized multi-center studies. HIV positive patients are treated in
the same way [6,10].
SUPPORTIVE CARE
Standardized supportive care guidelines should be included in
the protocol. This is important because nurses or doctors with no
formal training in pediatric oncology should be taught to safely
administer chemotherapy in the PODC setting.
To prevent vomiting, oral metoclopramide, 10 mg given
20 minutes before and 4 hours after CPM administration, is an
effective regimen. In patients who require leucovorin rescue,
the risk of vomiting (and MTX toxicity) may be further reduced
by the IM administration of chlorpromazine 0.5 mg/kg/dose.
The use of metoclopramide is prohibited in some countries. Ondan-
setron IM or IV at 5 mg/dose (or other 5-HT antagonists) is also
effective.
As many as 50% of patients may have stunting and/or malnu-
trition. Malnutrition increases the risk for infections. Nutritional
support is recommended and must consist of locally acceptable,
available, and affordable components [20–22].
The prevention of tumor lysis syndrome is of critical impor-
tance during the first days of treatment. The following strategy has
been used successfully in Malawi and Cameroon. Allopurinol
5 mg/kg three times daily 24 hours before the first dose of cyclo-
phosphamide, and continued for a total of 5 days. IV fluids are
commenced the day before chemotherapy, and continued for
72 hours at 3 L/m2/24 hours. Urinary excretion should be
3 ml/kg/hours. Furosemide is given to increase urinary excre-
tion if needed. Guardians, who normally stay with their child in
hospital, can be taught to collect the urine in soft drink bottles,
and report the volume to the nursing staff. Serum uric acid,
TABLE II. Risk Group Allocation on Day 28
Group 1 St Jude stages I and II in clinical remission
Group 2 St Jude stage III or stage uncertain, in clinical
remission and largest residual abdominal tumor
30 ml on ultrasound
Group 3 St Jude stage IV, or patient not in remission, or
residual abdominal tumor >30 ml on abdominal
ultrasound
Fig. 1. Twenty-eight-day treatment protocol for Burkitt lymphoma with cyclophosphamide and intrathecal methotrexate.
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electrolytes, and renal function tests are useful, but seldom
available. Failure to provide an adequate fluid intake and to
achieve the recommended urinary output, may result in metabolic
complications, and increase the risk for tumor lysis and early
death [6,11].
Fever is a medical emergency. Fever is defined as one recorded
temperature of 38.58C or two recorded temperatures of 38.58C
within a 24-hour period. Once malaria has been excluded, empiric
broad-spectrum antibiotics which cover Gram positive and Gram
negative organisms must be commenced as soon as possible. A
broad-spectrum penicillin (e.g., ampicillin) plus an aminoglycoside
(e.g., gentamicin) was used successfully in Malawi and Cameroon
as first line treatment. Therapy can be modified if a blood culture
result is available. If the patient remains febrile for >48 hours,
ceftriaxone or another third generation cephalosporin is recom-
mended. Nystatin is prescribed for mucositis. A course of acyclovir
is recommended as herpes simplex infection may be present [23]
Concomitant analgesics are essential. Morphine provides effective
pain relief. Hemorrhagic cystitis is largely prevented by ensuring a
fluid intake of 3 L/m2 in the 48 hours following CPM administra-
tion, and by instructing the patient to empty the bladder as frequent-
ly as possible [6,10].
MAIN ACUTE SIDE EFFECTS OF CHEMOTHERAPY
AGENTS
The healthcare providers should be taught, and the guardians
should be informed about the possible side effects of the different
chemotherapy agents used.
Fig. 2. Risk adapted therapy for Burkitt lymphoma.
TABLE III. Practical Notes are Listed
Chemotherapy should be administered on weekdays, when trained staff
is on duty to reduce the risk for errors
Chemotherapy must not be given unless the total white cell count is
1.0  109/L
Chemotherapy must be delayed if the patient has fever
Chemotherapy drugs must be mixed in a quiet, separate room with a
hood above the mixing surface, and the mixer should wear protective
clothing
A clinical photograph provides a record and assists in follow-up
Chemotherapy is also commenced in critically ill patients
Good control of drug stocks prevents shortages and waste
Vincristine sulfate causes irreversible fatal encephalopathy if injected
intrathecally inadvertently. The IT MTX and IT HC should not be
administered at the same time as the IV vincristine to avoid this
The cost of treatment should be guaranteed when treatment starts
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Co-Morbidities
Infections such as varicella, herpes Zoster, HIV, measles, and
parasitic infestations such as malaria and helminths should be
identified and treated according to national guidelines. Patients
who are HIV positive are given the same chemotherapy, irrespec-
tive of whether they are also receiving ARV treatment [6,10].
Palliative Care
This is an essential component of treatment. The palliative
care team should be introduced to the patient on first admission,
and will provide continued care if curative treatment fails.
SPECIAL CLINICAL PROBLEMS
Respiratory Obstruction
BL involving the neck and upper thorax may cause acute
respiratory obstruction. Patients with stridor or signs of upper
respiratory obstruction require an emergency, temporary tracheos-
tomy to prevent death. Intravenous corticosteroids may relieve
oedema and obstruction.
Paraplegia From Paraspinal Tumor Compression
Weakness/paralysis of the legs and incontinence may resolve
completely following chemotherapy. The shorter the delay in start-
ing treatment, the better is the chance of recovery. Patients with
unresolved paraplegia and incontinence are at risk of developing
progressive decubitus ulcers and infection. The rehabilitation of an
incontinent paraplegic child in a poor rural environment is difficult.
Traditional Medicine
This is an integral part of traditional African health care. Some
practices are harmful but despite this, traditional healers can be
counseled to identify and refer children with tumors to a hospital
where treatment is available [24].
Compliance With Treatment and Follow-Up
Failure to complete treatment and poor follow-up is largely
preventable. Proper counseling, critical assessment of the parent’s
resources, support (e.g., food) while in hospital, subsidized trans-
port for hospital visits, contact by mobile phone and, if needed,
home visits can achieve 95% compliance with treatment and
follow-up. The budget must include these additional costs [25,26].
Advocacy and Parent Support Groups
These are important measures to increase the number of
patients who can benefit from treatment. The dedicated nurse at
the treatment center is well equipped to provide advocacy and
develop parent support groups. The golden standard of care is the
best outcome that one can achieve with the available resources.
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